Innovation
Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.
Harness Therapeutics' CEO talked to In Vivo about the company's strategy for expansion and partnering in the neurodegeneration space.
Gingko Bioworks has released a large language model designed to improve mRNA stability.
Beyond the cost savings of biosimilars, the true evolution in wet AMD treatment is happening by companies developing next-generation therapies that aim to reduce injection burden, introduce novel mechanisms, and potentially alter disease progression.
The Centre for Commercialization of Regenerative Medicine has spent over a decade crafting a cell and gene therapy ecosystem in Canada. Now it is replicating the model abroad.
This is Part 1 of a 2-part profile of Hans Clevers, Head of Pharma Research and Early Development at Roche.
Artiva Biotherapeutics is hoping its NK cell therapy approach, which uses un-engineered cells, will prove effective in both oncologic and autoimmune indications and safe enough to be given in the community setting.
Boston-area biotech Apnimed expects Phase III readouts for its obstructive sleep apnea combination drug by May. Patients with OSA are desperate for a pill to treat the condition, and GLP-1 agonists are only part of the solution.
Having spun out its oncology business and put all of its eggs into a neuroscience-shaped basket, how is Alkermes executing on its 2024 stated strategy to return to its CNS roots?
Manu Chakravarthy, Roche’s head of the resurrected cardiometabolic division, lays out his four-pillared strategy to place the company in direct competition with Eli Lilly and Novo Nordisk.
As 2025 begins, the pharma industry is abuzz with discussions on pipeline strategies and China's growing role. With 30% of large pharma licensing deals now involving Chinese biotech, we take a whistlestop tour of the companies and regions driving this innovation.
The last quarter of 2024 was flush with venture financings for biotechs finding novel ways to incorporate AI into their processes.
In Vivo speaks with Ashley Zehnder, CEO of Fauna Bio, a company using AI to identify drug targets based on natural disease resistance in animals.
CHARM Therapeutics' CEO discusses its DragonFold technology, applying AI to cancer drug hunting, and the benefits of its Nobel Prize-winning roots.
Risk management and the need for back-up systems are fast emerging as themes that users of artificial intelligence tools in health care settings must face up to. Now more comfortable with the technology’s capabilities, health care stakeholders appreciate that there can be two sides to the AI coin.
One month after announcing a pipeline pivot, Ovid Therapeutics talked to In Vivo about the importance of making strategic decisions with discipline, and the imminent neurology revolution.
As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.
As India prepares to commercialize its first advanced therapies it must engage key stakeholders to ensure successful implementation. Learning from global best practices and managing pricing strategies will be crucial to maximize access, deliver high-quality outcomes, and sustain innovation through reinvestment in R&D.
Glen Clova Scientific is galvanizing virus-like particle technology with disruptive advances in manufacturing to treat immune-related dermatology conditions in often overlooked senile populations.
In this episode of the In Vivo podcast, Harvard immunologist and co-founder of early-stage biotech Corner Therapeutics, Jonathan Kagan, talks about harnessing the power of the innate immune system by weaponizing dendritic cells and creating immunotherapies that are safer and more durable.